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1 INTRODUCTION  
 
1.1 SPLICING DEFINITION  
 
Splicing is a complex process that revolutionized the gene concept since its discovery in the 
70s (Berget and Sharp, 1977; Gelinas and Roberts, 1977; Louise T Chow, Richard E. 
Gelinas, Thomas R., 1977). It soon became clear that the gene was not a simple functional 
unit or a heredity element, but rather a series of protein-coding sequences called exons, 
separated by long noncoding stretches called introns (Gerstein et al., 2007). Those introns 
must been excised from the gene transcript in order to obtain a mature mRNA. Some of 
them have an autocatalytic function (type I and II introns); and other are catalyzed by the 
spliceosome (spliceosomal introns, which are confined to the nuclear genome of all 
eukaryotes). The spliceosome is a complex ribonucleoprotein composed by five small RNAs 
(U1, U2, U4, U5, and U6 snRNAs) and more than 200 proteins (Rodríguez-Trelles et al., 
2006). Therefore, splicing process is defined as the removal of introns and subsequent 
rejoining of exons. 
The number of introns in a particular pre-mRNA can vary depending of the organism: in 
higher eukaryotes, it goes from zero to more than fifty (in vertebrates it ranges from 5.2 –
Fugu- to 7.9 –Gallus-, with 7.8 introns per gene in humans) (Sakharkar et al., 2004). 
Furthermore, whereas exons are relatively short (10-400 nucleotides), intron sizes can reach 
more than 200,000 nucleotides (Krämer, 1996; Sakharkar et al., 2004). Additionally, 
eukaryote genes suffer an interesting phenomenon, known as alternative splicing (AS), 
which consists in the generation of multiple transcript variants, by differentially processing 
introns and exons. This process can result in an on-off switch for a particular gene; it can 
expand gene molecular diversity (by generating different mRNA and protein isoforms); and 
also may explain the apparent low number of genes in eukaryotes, especially the ones 
whose AS rates are high (such as mammals -in humans for example, it occurs in 95% of 
multiexon genes-) (Claverie, 2001). 
 
AS patterns may vary from retention of introns or skipping of an entire exon, to more complex 
arrangements, as the production of multiple 5’ and 3’ splice sites (ss) within an intron, which 
would induce exon truncations/expansions (Irimia and Roy, 2014). These truncations 
generate prematurely terminated proteins upon translation, and can alter severely the 
protein function; so it may be expected this process would be highly regulated. Nonetheless, 
there remains a poorly understanding of the AS regulation and its functional implications (as 
it is not clear in which cases AS is functional or simply splicing “noise”) (Ast, 2004; Pajares 
et al., 2007). 
1.2 CONSTITUTIVE AND ALTERNATIVE SPLICING PROCESSES 
 
CONSTITUTIVE SPLICING: 
 
As it has been explained before, the excision of introns from pre-mRNAs by splicing process 
is an essential function in all eukaryotic organisms. In order to understand and classify this 
process, there have been described two types of spliceosomal introns. 1) The canonical 
introns (>99.5%) that start with the nucleotides GT and end with AG, and are catalyzed by 
the U2-dependent spliceosome. They are flanked by the 5’ and 3’ ss, which are called as 
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the splicing donor and acceptor. 2) The other ones are the non-canonical introns, which 
usually end with AT-AC, and are catalyzed by the U12-dependent spliceosome. They are 
found in vertebrates, insects, and plants, suggesting a common origin in those lineages with 
subsequent lost in many interior clades (Rodríguez-Trelles et al., 2006). 
Depending on the spliceosome type, intron defining information in a pre-mRNA must 
comprise different conserved sequences (see Figure 1): 1) the 5′ and 3′ ss; 2) the branch 
point (BP), whose localization is unknown (some authors estimate it as far of 3′ ss as 200 
nucleotides); and in higher eukaryotes, 3) a polypyrimidine tract or PPT, typically located 5-
16 nucleotides upstream from the 3’ss (Sieliwanowicz, 1988; Will and Lührmann, 2011). 
Usually, large introns contain numerous spurious recognition sites and this information is 
insufficient for proper spliceosomal recognition (Lynch, 2006), so it becomes necessary 
additional cis-acting information elements such as exonic and intronic splicing enhancers 
(ESEs and ISEs) or silencers (ESSs and ISSs). They are typically short and diverse in 
sequence - four to ten nucleotides in length- and modulate constitutive and alternative 
splicing by binding regulatory proteins (which control assembly of spliceosomal complexes 
at an adjacent splice site) (Sieliwanowicz, 1988; Will and Lührmann, 2011). 
Figure 1. Consensus cis-acting sequences of intron recognition. 
Pre-mRNA introns are removed by two trans-esterification reactions. First, within the intron, 
the 2′ OH group of the BP adenosine carries out a nucleophilic attack on the 5′ ss. Then, 
this site is cleaved and the 5’ ss is ligated to the BP adenosine, forming a lariat structure. 
Second, the 5′ exon 3′-OH group attack the 3′ ss, inducing the ligation of the 5′ and 3′ exons, 
and consequently, the intron release (Moore et al., 1993). In order for these reactions to take 
place, the spliceosome must assemble and interact with the pre-mRNA through two main 
splicing assembling pathways: the U2-dependent spliceosome, which is composed from the 
U1, U2, U5, and U4/U6 snRNPs and numerous non-snRNP proteins; and the U12-
dependent spliceosome, comprised by U11, U12, U5, and U4atac/U6atac snRNPs (Will and 
Lührmann, 2011). 
ALTERNATIVE SPLICING:  
Although splicing is a high-regulated process, there are deviations from a preferred gene-
splicing pattern to other forms of mature mRNA (see Figure 2). The exon recognition is given 
by the interaction between cis-acting elements and trans-acting factors (splicing code, 
Figure 3), which collaborate in the promotion or inhibition of spliceosome assembly around 
the weak splice sites. It has been seen that cis-acting elements function additively. 
Additionally, the enhancer elements have dominant roles in constitutive splicing, while the 
silencers have relatively more control in the alternative splicing. Cis-acting elements include: 
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1) the promoters, ESEs and ISEs (which are bound by positive trans-acting factors, such as 
SR proteins); and 2) the inhibitors, ESSs and ISSs (which are bound by negative acting 
factors, such as heterogeneous nuclear ribonucleoproteins –hnRNPs-) (Wang et al., 2014). 
 Figure 2. Types of splicing patterns. Continuous lines indicate splicing reactions of every 
pattern, while the discontinuous ones show the expected reaction of a canonical transcript. 
Referring to trans-acting factors, SR proteins are the most important positive-acting ones. 
They bind ESEs through their RNA recognition motifs (RRMs) and mediate protein 
interactions through their RS domains, which change its phosphorylation state during 
alternative splicing regulation. On the other hand, hnRNPs are the most important negative 
trans-acting factors. Their mechanisms of action are not fully understood, but it has been 
seen that they bind to the ESS excluding SR proteins, repress the spliceosome binding to 
the splice sites, or create a exon sequestration through the creation of a pre-RNAm loop 
(Han et al., 2010; Wang et al., 2014).  
 
 Figure 3. Cis-acting and trans-acting factors in splicing process. Green arrows indicate activation, 
and red lines indicate inhibition of splice site recognition. 
1.3 SPLICING MUTATIONS AND DISEASE 
 
ABERRANT SPLICING PATTERNS AND PATHOLOGY: 
 
As noted above, the splicing is a dynamical and high-regulated process that seeks the 
preservation of precise exon-intron junction recognition by the spliceosome, and the 
generation of different and functional mRNA variants, increasing the molecular diversity of 
eukaryote genes. In order to achieve that, there should be a correct conservation of splice 
sites, and an equilibrium of cis-acting and trans-acting factors (particularly important when 
a gene has large introns and spurious recognition sites) (Lynch, 2006; Sieliwanowicz, 1988; 
Will and Lührmann, 2011). However, if splicing elements were mutated, they would induce 
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an aberrant splicing pattern, causing disease, increasing its susceptibility or modifying the 
severity of the deleterious phenotype (Padgett, 2012; Wang and Cooper, 2007). 
Remarkably, recent evidence shows how the splicing motifs as mutational targets may 
induce a range of 15% to more than 60% of human genetic disorders (Acedo et al., 2015; 
Lynch, 2006; Wang and Cooper, 2007).  
 
This wide range of splicing mutations associated with genetic diseases suggests: in first 
place, our lack of knowledge about the splicing code; second, the deficiency in spliceogenic 
variant detection; and then, the necessity of increasing research in this topic (Wang and 
Cooper, 2007). There are important evidences that support these assertions: 1) 300 genes 
with splicing mutations are associated with 370 diseases (Wang et al., 2012); 2) at least 
10% of the inherited diseases are related with mutations upon intron-exon junction (Padgett, 
2012); and 3) It seems that mutations outside the canonical splice sites may account for a 
bigger percentage, since this type of variants have been routinely overlooked (Krawczak et 
al., 2007; Padgett, 2012).  
 
Although it is prevailing the research conducted through the roles of splicing in disease, it 
already has given us insights about the splicing mechanisms and its regulation. For 
example, the discovery that most pathogenic 5′ ss mutations give rise to exon skipping rather 
than intron retention, supports the exon definition concept; or, that the effects of exon 
mutations on splicing contributed to the description of splicing code. Technology advances 
(which must be understood as new molecular biology techniques and high-throughput 
methods) will allow the implementation of these discoveries in clinic, and the knowledge 
application toward diagnosis and treatment. In order to successfully predict the effect of 
splicing mutations in disease, it is necessary to implement an holistic approximation, which 
integrates computational methods with experimental evidence (Wang and Cooper, 2007).  
 
Researchers have also classified different types of splicing mutations effects on disease. 
Cis-acting mutations comprise splice site variants, single-nucleotide substitutions, and micro 
insertions/deletions. These variants take place primarily within exons, which can cause a 
splicing defect, rather than changes in the predicted protein-coding sequence (since 
aberrant splicing and mRNA degradation mechanisms prevail over mutated protein 
expression). The uncertainty about the influence of these variants on disease is due to its 
ample range of sensitivities within a specific gene, which is directly related with the binding 
of the splicing elements (Wang and Cooper, 2007). Trans-acting mutations involve defects 
in the splicing machinery. Normally, a null mutation in the basal splicing machinery leads to 
lethal consequences (Faustino et al., 2003). Despite this observation, there are two diseases 
associated with the assembly or function of the snRNPs, in which two different groups of 
neurons are affected: spinal muscular atrophy and retinitis pigmentosa. Additionally, there 
are diseases linked with trans-acting mutations (which are related with the disruption of 
alternative splicing regulators), such as myotonic dystrophy or cancer (Faustino et al., 2003; 
Wang and Cooper, 2007). While a cis-acting mutation is expected to be restricted to a 
specific exon, a trans-acting one may have a global effect (because these regulate 
thousands of alternative splicing events in the transcriptome) (Acedo, 2013; Wang and 
Cooper, 2007). Furthermore, it is necessary to consider that a specific mutation effect may 
range from being the disease cause to affecting its susceptibility. 
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SPLICING MUTATIONS IN CANCER: 
During cancer progression, a common feature involves the aberrant splicing of the genes 
implicated. The main affected genes throughout the transition from a normal cell function to 
the development of malignancy are those that regulate apoptosis, cell migration, cell growth, 
hormones responsiveness, cell–cell and cell–matrix interactions, and response to 
chemotherapy. Currently, the evidence has shown how cis-acting mutations on oncogenes, 
tumor suppressors and other cancer-relevant genes have a direct impact in cancer initiation 
and progression; however, the majority of the splicing changes must be due to trans-acting 
mutations, since there is no detection of changes within the genes involved. Besides these 
findings, there remain several important issues about the role of splicing in cancer. In first 
place, there is uncertainty about the extent of influence of splicing mutations on cancer 
initiation and progression. Second, if the previous premise is true, what are the most 
important genes involved in this process? Third, what is the effect of such mutations on the 
protein expression and properties? Those questions give rise to an ample range of diagnosis 
and therapeutic possibilities such as: the use of the alternative splicing signatures to predict 
a pathological outcome and evaluate a treatment efficiency; or the development of drug 
searching using cancer-specific splicing patterns as targeting mechanism (Faustino et al., 
2003; Wang and Cooper, 2007). According to the literature, cancer-associated mutations in 
cis-elements (inherited or acquired) are being underestimated. Though there are many 
examples of this type of cancer-associated alterations, in only a few cases a cause-effect 
relationship has been proved (Srebrow and Kornblihtt, 2006). This is due to the traditional 
mutation screening approach, which focuses on the primary structure analysis of genomic 
DNA, and predicted protein effect, ignoring alterations on splicing. 
First, as cancer-associated splicing mutations are studied, there are being gathered more 
genes related to them. One example is Adenomatous Polyposis Coli gene (APC) which 
contains a AG>AT mutation on the acceptor site of the exon 4, frustrating its recognition, 
and implicating it in hepatic and colorectal cancer (Kurahashi et al., 1995). Others cancer-
associated genes also have this kind of genetic variants, such as the tumor suppressor gene 
hSNF5, the estrogen receptor gene (ER), the neurofibromatosis type 1 and 2 genes (NF1 
and 2), the tumor suppressor (LKB1), the oncogene KIT, the liver intestine cadherin 
(CDH17), and the Kruppel-like Znfinger transcription factor gene (KLF6) (Colapietro et al., 
2003; De Klein et al., 1998; Srebrow and Kornblihtt, 2006; Taylor et al., 2000; Wang et al., 
1997). Second, in order to determine the real frequency of splicing variants, it is required a 
comparative analysis of DNA, mRNA, and even protein sequences. To exemplify this point, 
a study of 80 unrelated patients with neurofibromatosis type 1 was conducted to show how 
the percentage of splicing mutations varies according to the nucleic acid used during the 
analysis: it increased from 37% to 50%, by shifting from DNA to mRNA analysis. Third, it is 
a fact that some exonic nonsense mutations are associated with exon skipping rather than 
the introduction of a premature stop codon (Pajares et al., 2007). 
Regarding to cancer-associated trans-acting mutations, it has been found a correlation 
between the splicing regulatory factor expression (mostly SR proteins and hnRNPs) and the 
aberrant alternative splicing transitions, which are associated with malignant transformation 
(Faustino et al., 2003). One of them is related to changes of the relative abundance of 
specific SR proteins during cancer progression. These changes can be used as a pre-
neoplasia marker, nonetheless, they are not predictive in the determination of tumor 
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incidence or invasiveness, which indicates that they are only one factor within a complex of 
cellular changes for neoplasia and malignancy (Faustino et al., 2003). An increase of SR 
protein expression is associated to mammary gland tumorigenesis in a well-characterized 
mouse model and various human cancers (Kaida et al., 2012; Nowak et al., 2008; Stickeler 
et al., 1999). In addition, hnRNP protein family is also implicated in cancer development 
controlling alternative splicing of the IG20/MADD and Ron genes (Kaida et al., 2012).  
HEREDITARY BREAST AND OVARIAN CANCER (HBOC): 
Breast cancer is the most common malignancy and the second most common worldwide 
cause of death by cancer in women. In 2012, 1.67 million new cases were diagnosed, 
reaching a 25% of all cancers in females. The statistics indicate that one in eight people of 
this gender will suffer from this disease. Additionally, if she has first-degree relatives who 
suffer of breast cancer, her risk of developing the disease is twice than general population. 
This hereditary component of the pathology, which is called hereditary breast and ovarian 
cancer (HBOC), ranges from 10% to 30% of the cases (25–40% when the patients are under 
35 years old). However, only 5%–10% are identified with a strong inherited component, and 
4%-5% are explained by mutations in high penetrant genes, which have an autosomal 
dominant inheritance (Stratton and Rahman, 2008).  
The most important high penetrant genes involved in HBOC are the breast cancer type 1 
and 2 susceptibility genes (BRCA1 and BRCA2), which cause 16% of HBOC cases, and 
whose pathogenic variants multiply the risk of developing breast cancer between 10 to 20 
times. The HBOC predisposition has an autosomal dominant inheritance throughout families 
who carry mutations in the BRCA genes; however, at cellular level, they act as recessive 
genes (Lux et al., 2006). These genes encode nuclear phosphoproteins, which have tumor 
suppressor activity, through the maintenance of genomic stability. Despite they act in a 
common genome protection pathway, they have different roles: BRCA1 is a protein involved 
in checkpoint activation and DNA repair, whereas BRCA2 is involved in the core mechanism 
of homologous recombination. Currently, the associations between these proteins remains 
undefined, but it is clear they must exist, since the germline mutations of the genes have an 
obvious similarity regarding their cancer susceptibility (Roy et al., 2011). 
BRCA1 gene has 81.19 Kb of genomic sequence that contains 23 exons, 22 of them protein-
coding. Its transcription generates an mRNA of 7094nt, whose translation produce a protein 
of 1863 aminoacids and 220 kDa. The protein contains several functional domains (Figure 
4): 1) an amino-terminus RING domain, which is important for the interaction with other 
proteins; 2) a pair of nuclear localization signals (NLS) in the core region; 3) several 
phosphorylation sites; 4) a helical domain to interact with PALB2 and BRCA2; and 5) a 
BRCT domain at the C terminus. The protein interacts with other proteins to form the 
BRCA1-associated genome surveillance complex, which participates in regulating multiple 
cellular processes as: gene stability maintenance, cell cycle control, ubiquitination, 
transcription, chromatin remodeling and p53-independent apoptosis (Linger and Kruk, 
2010). Mutations within this gene cause a risk of breast and ovarian cancer as high as 80% 
and 40%, respectively (Apostolou and Fostira, 2013).  
On the other hand, BRCA2 is involved in the repair of double-strand DNA breaks (DSBs) 
through the homologous recombination (HR) pathway. It is a large gene, which comprises 
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27 exons (26 of them protein-coding) and 84.2 Kb. The BRCA2 resulting protein contains 
3418 amino acids and 384 KDa. It has several functional domains (see Figure 4): 1) at the 
N-terminus it has a PALB2 interaction domain; then, within the gene, it contains 2) eight 
BRC repeats that bind the RAD51 recombinase; at the C-terminus a 3) DNA-binding domain 
(DBD), whose functions is the binding with single and double stranded DNA (Roy et al., 
2011). It has been found that male carriers of BRCA2 mutations have a risk of 20% of 
developing prostate cancer, a 6% of breast cancer, and a 3% of pancreatic cancer. Female 
carriers have a risk between 26% to 84% for breast cancer, and 20% for ovarian cancer 
(Apostolou and Fostira, 2013). A large number of pathogenic variants are classified as 
frameshift and nonsense, but most DNA changes (including ~900 different missense 
mutations from the BIC database) are variants of unknown clinical significance (VUSs) 
(Apostolou and Fostira, 2013).  
 
 
Figure 4. Functional domains of BRCA1/2 proteins.  
Green circles indicate the interaction with other proteins 
Research focusing on the BRCA1 and BRCA2 aberrant genetic variants have barely linked 
them to 16% of cases of HBOC, since there is a high number of inconclusive results due to 
variants of unknown significance. Then, how to explain the 80% remaining cases with a 
strong family HBOC record? There have been proposed several approaches to answer this 
question: first, researchers have identified different mutated genes that conferee a moderate 
risk (as ATM, BRIP1, CHEK2, PALB2, or RAD51), nonetheless, their frequency is very low 
to explain this high percentage (Acedo, 2013). These genes mostly codify proteins involved 
in DNA repair, but there is no explanation to the question of why damage of these genes 
specifically increase the susceptibility to HBOC. The most accepted theory suggests that 
menstrual cycle causes oxidative DNA damage driven by hormonal growth. This oxidative 
DNA damage induces replication stress and consequently, DSBs, which requires the 
BRCA1–BRCA2–HR pathway to be repaired (Roy et al., 2011). 
Second, genome-wide association studies have identified 41 common single nucleotide 
polymorphisms (SNP) associated with the HBOC susceptibility, however the authors 
suggest that more than 1,000 additional loci are involved (Michailidou et al., 
2013). This evidence suggest the importance of determining the real effect of the 
unclassified BRCA1/2 genetic variants, which constitute the major limitation of BRCA1 and 
BRCA2 genetic testing. Most VUSs are mainly missense but also can be intronic or even 
silent variants. The interpretation of such variations constitutes a diagnosis problem, which 
jeopardizes the HBOC prevention and surveillance protocols. Currently, there are multiple 
approximations to evaluate the possible effect of a VUS variant. The in silico analysis tries 
to estimate the variant phylogenetic conservation and the possible protein modification it 
causes. Additionally, there are variant and disease segregation analysis; however, the best 
8 
 
way to improve the HBOC genetic testing is to clarify the functional effect of the VUS 
(Apostolou and Fostira, 2013).  
SPLICING MUTATIONS WITHIN BRCA GENES: 
At present, there are specialized DNA databases, which compile the updated BRCA1/2 
reported variants. The Breast Cancer Information Core -abbreviated as BIC- 
(http://research.nhgri.nih.gov/bic/) is one of the most important. At May of 2015, this 
database has reported 1781 BRCA1 variants, and 2000 to BRCA2. Most of them are single-
nucleotide substitutions, but also there are small insertions and deletions. BIC database 
classifies the mutations according to the protein translation predicted effect: as frameshift, 
nonsense, missense, or synonymous. Additionally it indicates the in frame Ins/Dels, the 
mutations within introns or UTR regions, and finally those that alter the splicing process.  
Interestingly, about one-half of the total BIC reported variants remain as VUSs. Our 
laboratory formerly has reported one third of disease-causing variants as splicing-disrupting 
(belonging to 14 exons of BRCA1/2) (Acedo et al., 2012; Sanz et al., 2010). Furthermore, 
recent studies showed that splicing variants are enriched in cancer-related genes (Acedo et 
al., 2015; Sterne-weiler and Sanford, 2014). The characterization of an aberrant splicing 
variant is a complex task, which requires a functional validation, since a completely accurate 
bioinformatic prediction of its effect on the mRNA processing is not currently available (a 
number of studies have failed to confirm experimentally the initial in silico findings). 
Subsequently, there is an increasing research effort to describe the functional effect of such 
variants, in both BRCA1 and BRCA2, and its relationship with HBOC. Just to give an 
example, the first proved splicing deleterious variant of BRCA1 was an inherited mutation in 
exon 18, classified as nonsense. It actually disrupts an ESE sequence and provokes exon 
18 skipping (Mazoyer et al., 1998). Since then, the splicing enhancer and silencer mutation 
descriptions have considerably grown (Srebrow and Kornblihtt, 2006). There are also 
examples of BRCA2 that have been deeply described: 
1) The c.145C>T mutation within exon 3 is already annotated at BIC as nonsense. Our 
laboratory demonstrated that it actually affects splicing, causing a high percentage 
of transcripts with exon 3 skipping. Bioinformatic analysis indicates that it eliminates 
an ESE sequence that binds to the SF2/ASF factor (Sanz et al., 2010). 
 
2) The c.470_474del5 mutation in exon 5 is registered in the BIC database as 
frameshift. This mutation affects splicing by excluding the majority of exon 5, due to 
the elimination of a ESE sequence (Sanz et al., 2010).  
 
3) The mutation c.8331G>A in exon 18 initially had an unknown clinical effect. Splicing 
functional assays have shown that it alters exon 18 donor site causing exon skipping. 
The variant finally causes the production of a truncated protein (Sanz et al., 2010). 
 
4) It has been proved that missense mutations with an unknown clinical effect can alter 
splicing. The c.517G>T in exon 7 of BRCA2, does it. In this particular example, a 
significant percentage of transcripts have exon 7 skipping, due to the disruption of 
the acceptor sequence (Gaildrat et al., 2012). 
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5) Normally, intronic splice site mutations are classified as clinically significant, since 
they affect splicing. However, there are other deleterious intronic variants, as the 
c.6937+594T>G within the intron 12 of BRCA2. It activates a cryptic splicing site, 
inducing the a pseudo-exon introduction in the mature mRNA (Anczuków et al., 
2012). There are other examples as the intron 2 PPT mutation c.68-7T>A, which 
promotes partial exon 3 skipping (Sanz et al., 2010). 
Altogether, these results demonstrate how crucial is to implement holistic approaches to 
interpret the molecular basis of a genetic disease, and to define the nucleotide substitutions 
within coding regions that act at the translational or the splicing level. In order to achieve 
this, it is necessary to combine the use of bioinformatics tools with RNA functional assays, 
which can be developed though the implementation of RT-PCR from patient’s RNA samples, 
or by the use of hybrid minigenes. The first one is the most straightforward and direct method 
to assess the clinical relevance of DNA changes, but collecting patient samples is a difficult 
task, so it is possible to overcome the issue by using the hybrid minigene technology.  
This work focuses on the study of splicing variants within the exon 17 of BRCA2. 
Remarkably, it possesses a non-canonical GC donor site, which represents less than 1% of 
these motifs, compared with the canonical GT site. In the non-canonical donor site exons, it 
is expected that the other nucleotides in the signal adhere more closely to the consensus 
sequence (A/C)AG|GC(A/G)AGT, apparently, compensating for the T to C substitution that 
is unfavorable for splicing. This rare class of donor splice signals also has been implicated 
in alternative splicing, being highly important the signal strength for splice site selection 
(Churbanov et al., 2008; Thanaraj and Clark, 2001). Based on this premise, splicing variants 
within this exon are more susceptible of being deleterious, which becomes it interesting for 
the study of its regulation. 
 
1.4 HYPOTHESIS 
 
A large proportion of DNA variants of any type alters pre-mRNA splicing in many human 
inherited diseases, including HBOC. 
 
1.5 OBJECTIVES 
 
GENERAL 
We aim to assess exon 17 splicing variants involvement in the genetic susceptibility to 
HBOC, by a bioinformatic analysis and mRNA functional assays through a hybrid minigene 
strategy. 
SPECIFIC 
 
1) To select the candidate variants of the functional analysis based on a bioinformatic 
prediction, using online databases as BIC and algorithms as the presented on the 
Human Splicing Finder Database (HSF). 
2) To construct and validate a wild type minigene that contains the 14-20 exons of 
BRCA2 and can be used as a vector of the functional analysis. 
3) To generate each of the selected BRCA2 variants within the minigene.  
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4) To perform a functional analysis of the variants (driven in eukaryote cells), in order 
to evaluate its effect on the mRNA splicing. 
5) To characterize the new-generated splicing patterns. 
6) To contribute to the understanding of the HBOC genetic predisposition spectrum. 
2 MATERIALS AND METHODS  
 
2.1 BIOINFORMATIC ANALYSIS OF SPLICING VARIANTS 
All the BRCA2 exon 17 reported variants were searched at two BRCA databases: the BIC 
and the Universal mutation –UMD (http://www.umd.be/) (Caputo et al., 2012). Then, the 
mutant and normal sequences were analyzed with several bioinformatic tools to identify 
potential splicing mutations. Disruption/creation of splice sites was evaluated with 
NNSPLICE version 0.9 (http://www.fruitfly.org/seq_tools/splice.html) (Reese et al., 1997). 
Additionally, the human splicing finder -HSF version 2.4.1 (http://www.umd.be/HSF/) 
(Desmet et al., 2009) was used to predict branch point disruptions, enhancer and/or silencer 
modifications. Specifically, HSF computational tools predict disruption of SR proteins binding 
motifs such as SRp40, SC35, SF2/ASF, SRp55, hnRNP A1 (repressor), Tra2-b, and 9G8 
protein binding motifs. The criteria to select the splicing variants that would be object of a 
functional analysis were: 1) acceptor or donor sites elimination or significant score reduction; 
2) generation of new splice sites, mainly exonic ones; 3) disruption of the branch point; 4) 
mutations localized within positive microdeletions; 5) disruption of enhancer motifs or 
creation of silencers, focusing on hnRNPA1. 
After the selection of the BRCA2 DNA variants, the site directed mutagenesis primers were 
designed, by using Oligo 7 software (Molecular Biology Insights, Inc. DBA Oligo, Inc. 
Vondelpark, CO, USA).  
2.2 CONSTRUCTION OF THE BRCA2 EXON 14-20 MINIGENE 
The BRCA2 exon 17 mutation variants were introduced in the pSAD-minigene with exons 
14-20 of BRCA2. It produced a canonical transcript of the expected exon composition and 
size (1809 nucleotides). This new splicing plasmid, pSAD (Patent P201231427-CSIC, 
Priority Patent Application filed), has a pSPL3 backbone with the following features: 1) intron 
size reduction of 1.2 kb; 2) introduction of Beta-Galactosidase (LacZ) as a second selection 
marker; 3) a new polylinker with 27 restriction sites (pSPL3, 10 sites); 4) a vector exon V2 
acceptor site strengthening (NNSPLICE score 0.99 vs. 0.64) by triple mutagenesis; and 5) 
elimination of old pSPL3 restriction sites (HindIII, XbaI, and SalI) that interfere with those of 
the new multiple cloning site (MCS). 
MGBR2EX14-20 (see Figure 5) was constructed in four steps, which comprise overlapping 
extension PCR or classical restriction digestion/ligation cloning. The construction process 
had three intermediate constructs: MGBR2EX17-18, MGBR2EX16-18, and MGBR2EX16-
20. All the inserts were amplified with Phusion High Fidelity polymerase (Life Technologies, 
Carlsbad, CA, USA) and primers indicated on Table 1. Exons 17-18 were subcloned into the 
pSAD vector by an overlapping extension PCR. Then, exon 16 was added by the same 
technique. Exons 19-20 were inserted by cutting with Xhol and BamHI restriction enzymes, 
both the vector and the PCR product that contains the exons 19-20, and by ligating the 
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fragments. Finally, a similar process was conducted to introduce the exons 14-15, using the 
EagI and SacI restriction enzymes. To conclude, after each step of the minigene 
construction, a functional analysis was conducted to evaluate whether they generate a 
correct splicing pattern. 
Table 1. Primers used on the MGBR2EX14-20 minigene. 
Primer 5'-3' Sequence Size 
MGBR2_ex14-15-SacIFW CACACAGAGCTCTGAAGATGTGAAGGTGAGAGAA 2405 
MGBR2_ex14-15-EagIRV CACACACGGCCGGTTCAGGGCTATCAGTTATTCA 
MGBR2_ex17-18_Ins-FW GCTCTAGAACTAGTGGATCCCCCGGTCAGTATGATACTTTGATACATGT 1556 
MGBR2_ex17-18_Ins-RW ATAAGCTTGATATCGAATTCCTGCAGTGGAATAGGGATCTGATCAA 
MGBR2_ex16_Ins-FW GCTCTAGAACTAGTGGATCCCCCGGCCCTTTTGTTTCCCATCTAAGT 805 
MGBR2_ex16_Ins-RW GACATGTATCAAAGTATCATACTGAATAAATGCCTAAGAAAAATGT 
MGBR2_ex19-20_XhoI-FW CACACACTCGAGATAGCATTAAGAACTTGTAGCA 1188 
MGBR2_ex19-20-KpnI-RV CACACAGGTACCATTACAAATGGCTTAGACCTGA 
 
 
Figure 5. MGBR2EX14-20 structure inside the pSAD vector. The four cloning steps are shown as 
dashed green boxes. Arrows indicate expected splicing reactions in eukaryotic cells. 
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2.3 SITE-DIRECTED MUTAGENESIS 
Mutagenesis was carried out with the Quick-change Lightning Site-Directed Mutagenesis kit 
(Agilent, Santa Clara, CA, USA). Wild type (wt) minigene MGBR2ex14–20 was used as 
template to generate 14 bioinformatically selected DNA variants, and confirmed by 
sequencing. Each mutant clone was cultured at 37 ºC for 24 hours, in LB liquid medium 
(Broth-LB Miller, Merk) supplemented with ampicillin at a final concentration of 100 ug/ml. 
Plasmid DNA minigenes were purified with the AccuPrep Plasmid Extraction kit (Bioneer, 
Alameda, CA, USA), and were stored for the subsequent analysis steps. 
DNA was quantified with a Quawell 3000 Nanodrop spectrophotometer (ThemoScientific, 
Waltham, MA, USA), and then sequenced with the BigDye Terminator Cycle kit Sequencing 
v3.1 (Applied Biosystems, Carlsbad, CA, USA) following the manufacturer's instructions, 
adding 25ng/Kb of DNA, and depending on the variant position, primers that allow the 
mutagenesis identification: RT18-RV (5’TCCCTTTCCATTATCTTTTT3’) or RT16-FW 
(5’TATGGACTGGAAAAGGAATAC3’). The capillary electrophoretic run was conducted in a 
sequencer automatic ABI Prism 3130 (Applied Biosystems) with a 36 cm- capillary array, 
using polymer POP-7 (Applied Biosystems) and running buffer with EDTA (Applied 
Biosystems). The analysis of chromatograms was performed with SnapGene 2.7.2 software 
(GSL Biotech LLC, Chicago, IL, USA). 
2.4 FUNCTIONAL ANALYSIS OF SPLICING VARIANTS 
Transfection of HeLa cells: 105 HeLa cells (human cervical carcinoma) were grown to 90% 
confluence with 0.5 ml of medium (DMEM, 10% fetal bovine serum, 1% glucose, and 1% 
penicillin/streptomycin) in four-well plates (Nunc, Roskilde, Denmark). Cells were transiently 
transfected with 1μg of each minigene and 2μl of Lipofectamine 2000 (Life Technologies). 
After 48 hours, nonsense-mediated decay (NMD) was inhibited in the cell culture by adding 
cycloheximide (Sigma–Aldrich, St. Louis, MO, USA) at a final concentration of 300μg/ml. 
After four hours, RNA was purified with the GeneMATRIX Universal RNA Purification Kit 
(EURx, Gdańsk, Poland) with on-column DNAase I treatment. 
RT-PCR was carried out with 100 ng of RNA and the RevertAid H Minus First Strand cDNA 
Synthesis Kit (Life Technologies), using gene specific primer RTPSPL3-RV 
(5’TGAGGAGTGAATTGGTCGAA3’). Samples were incubated 25°C for 5 min, 42°C for 1 
hour, and a final extension step at 70°C for 5 min. Then, cDNA was amplified with RTPSPL3-
RV and RT16-FW using Platinum Taq DNA polymerase (Life Technologies). The final 
transcript had an expected size of 1015 nucleotides. 
Previous purification of the cDNA with the AccuPrep PCR Purification kit (Bioneer), 
sequence reactions were performed using the kit BigDye Terminator v3.1 Cycle Sequencing 
Kit (Applied Biosystems) following the manufacturer's instructions. Semiquantitative 
fluorescent RT-PCRs were done in triplicate with a RT16-FW FAM-labeled primer. Seven 
nanograms of DNA from the FAM-labeled RT-PCR products was mixed with 20μl of Hi-Di 
Formamide and 1μl of LIZ-1200 Size Standard (Life Technologies). Samples were run on 
an ABI3130 sequencer and analyzed with the Peak Scanner software (Applied Biosystems). 
Only peaks with heights ≥ 50 RFU (Relative Fluorescence Units) were taken into account. 
Mean peak areas of each transcript and standard deviations were calculated. 
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3 RESULTS 
 
3.1 BIOINFORMATIC ANALYSIS OF SPLICING VARIANTS 
 
Sixty-six DNA variants within exon 17 of BRCA2 were identified from the database search. 
Using the selection criteria, fourteen of them were finally chosen for functional analysis, and 
site directed mutagenesis primers were designed (Figure 6 and Table 2). According to the 
BIC and UMD annotations, five mutations were classified as Intervening sequences 
(intronic), five as missense mutations, two as frame shift mutations, and two as synonymous.  
 
 
Figure 6. Exon 17 selected variants localization.  
The different colors indicate the main criteria used to the selection. 
 
When these results were contrasted with the bioinformatic analysis, eight variants were 
found to induce changes in the splice sites scores, affecting the ss consensus sequences, 
and then, they were selected for functional analysis. Three of them were associated with the 
acceptor site (c.7806-2A>G, c.7806-1G>T and c.7806insAG), and five with the donor site 
(c.7975A>G, c.7976G>C, c.7976G>T, c.7976+1G>A and c.7976+5G>T). Bioinformatics 
also predicted one disruption on a branch point site (c.7806-40A>G), and multiple enhancer 
disruptions and/or silencer creations (c.7819A>C and c.7829dup), which were also 
associated and prioritized if they belonged to a previously identified positive microdeletion 
region with putative active ESEs (Acedo, 2013) (c.7947A>G, c.7952G>T and c.7971A>G).  
 
3.2 MINIGENE CONSTRUCTION 
 
Since it is very difficult to obtain patient samples to test the presence and effect of BRCA2 
splicing variants, we opted to study the selected variants with a hybrid minigene approach. 
MGBR2EX14-20 was constructed in several cloning steps, as previously described (Acedo, 
2013). Before the functional analysis, it was necessary to guarantee the fidelity and 
reproducibility of the minigene, which had to be able to create an adequate genomic context 
for variant analysis of exon 17 of BRCA2, object of this study. Therefore, each intermediate 
construct was functionally assayed. The amplification products were run on an 
electrophoresis gel and its size was checked (see Figure 7).  
14 
 
Table 2. Bioinformatic analysis of the variants selected to functional assay. 
 [+] and [-] symbols indicate creation or disruption, respectively, of splicing regulatory sequences.  
DNA variant Source Variant type Bioinformatics2 Site-directed Mutagenesis primers (5’- 3’) 
c.7806-40A>G BIC 
Intervening 
Sequence 
 
HSF: [-]branch site 45 nt upstream (67.63→38); 
[+]SRp55; [+]PESEs (26.79); [-] 2Sironi ESS (63.33; 
61.92); [+]Fas-ESS; [-] hnRNP A1(66.19) 
FW:GTTGAATTCAGTATCATCCTGTGTGGTTTTTATGATAATAT 
RV:ATATTATCATAAAAACCACACAGGATGATACTGAATTCAAC 
c.7806-2A>G BIC 
Intervening 
Sequence 
[-] Aceptor site (NNS: 0.95 →<0.4); 
[-]9G8 (59.87); [+] 3 Sironi ESS (75.30;65.03;70.71); 
[-] hnRNP A1(82.86) 
FW:TCTACTTTTATTTGTTCGGGGCTCTGTGTGACACT 
RV:AGTGTCACACAGAGCCCCGAACAAATAAAAGTAGA 
c.7806-1G>T BIC 
Intervening 
Sequence 
[-] Aceptor site (NNS: 0.95 →<0.4);  
 [-]SC35; [+] 2 ESS Zhang; [-] hnRNPA1 (82,86) 
FW:CTACTTTTATTTGTTCATGGCTCTGTGTGACACTC 
RV:GAGTGTCACACAGAGCCATGAACAAATAAAAGTAG 
c.7806insAG BIC Frame shift  
[-] Aceptor site (MaxEnt: 5.95 → -14.25); 
 [+]hnRNPA1 (82,86) 
FW:TCTACTTTTATTTGTTCAGAGGGCTCTGTGTGACACTCC 
RV:GGAGTGTCACACAGAGCCCTCTGAACAAATAAAAGTAGA 
c.7819A>C BIC Missense  
[-]SF2/ASF (72.31), [-]SC35 (77.63), [-] 2 SRp40 
(78.98;85.27); [+] 2 Sironi ESS (62.90; 63.22) 
FW:TGTTCAGGGCTCTGTGTGACCCTCCAGGTGTGGATCCAAAG 
RV:CTTTGGATCCACACCTGGAGGGTCACACAGAGCCCTGAACA 
 
c.7829dup UMD Frame shift  
[-]SC35 (83.34), [-] 2 SRp55 (78.60); [-] 2 Rescue-
ESE; [-] 9G8 (64.90); [+] 2 Fas-ESS 
FW:TCTGTGTGACACTCCAGGTGTTGGATCCAAAGCTTATTTCTA 
RV:TAGAAATAAGCTTTGGATCCAACACCTGGAGTGTCACACAGA 
 
c.7947A>G1 BIC Synonymous 
[-]SF2/ASF (77.23), [-] SRp40 (79.40); 
 [-] Rescue-ESE); [-] Sironi ESS (64.11) 
FW:GCTAATAGATGCCTAAGCCCGGAAAGGGTGCTTCTTCAACT 
RV:AGTTGAAGAAGCACCCTTTCCGGGCTTAGGCATCTATTAGC 
c.7952G>T1 UMD Missense  
[-] SRp40 (79.40); [-] Rescue-ESE); 
 [-] 2 Sironi ESS (64.93;61.98); [+] PESEs (28);  
[-] hnRNP A1 (83.81) 
FW:TAGATGCCTAAGCCCAGAAATGGTGCTTCTTCAACTAAAAT 
RV:ATTTTAGTTGAAGAAGCACCATTTCTGGGCTTAGGCATCTA 
c.7971A>G1 UMD Synonymous [-] 2 Tra2-β (81.02;85.42); [+]hnRNPA1 (70,48) 
FW:AGGGTGCTTCTTCAACTAAAGTACAGGCAAGTTTAAAGCAT 
RV:ATGCTTTAAACTTGCCTGTACTTTAGTTGAAGAAGCACCCT 
c.7975A>G BIC Missense  
[-] GC donor site (MaxEnt: 3.61 → -4.34); 
 [-] SRp40 (91.86), [+] SRp55 (75.65);  
[-] hnRNPA1(79.29) 
FW:CTTCTTCAACTAAAATACGGGCAAGTTTAAAGCATTA 
RV:TAATGCTTTAAACTTGCCCGTATTTTAGTTGAAGAAG 
c.7976G>C BIC Missense  
[-] GC donor site (MaxEnt: 3.61 → -4.45); 
 [+]SF2/ASF; [+] Rescue-ESSs; 
[-] 2hnRNPA1 (74.76, 66.43) 
FW:TTCTTCAACTAAAATACACGCAAGTTTAAAGCATTAC 
RV:GTAATGCTTTAAACTTGCGTGTATTTTAGTTGAAGAA 
c.7976G>A BIC Missense  
[-] GC donor site (MaxEnt: 3.61 → -5.13); 
 [-] Sironi ESS (69.76);[-] 2 hnRNPA1(74.76;66.43) 
FW:GCTTCTTCAACTAAAATACAAGCAAGTTTAAAGCATTACAT 
RV:ATGTAATGCTTTAAACTTGCTTGTATTTTAGTTGAAGAAGC 
c.7976+1G>A BIC 
Intervening 
Sequence 
[-] GC donor site (HSF: 73.16 →43.33); 
 [-] SRp40 (91.86); [-] Sironi ESS (69.76);  
[-] hnRNP A1(74.76) 
FW: TCTTCAACTAAAATACAGACAAGTTTAAAGCATTACA 3 
RV: TGTAATGCTTTAAACTTGTCTGTATTTTAGTTGAAGA  
c.7976+5G>T BIC 
Intervening 
Sequence 
[-] GC donor site (MaxEnt: 3.1 →1.01); 
 [-] 2 Fas-ESS [+] PESEs (32.82) 
FW: CAACTAAAATACAGGCAATTTTAAAGCATTACATTAC  
RV: GTAATGTAATGCTTTAAAATTGCCTGTATTTTAGTTG  
1 These variants belong to a positive microdeletion region with putative ESE sequences.  
2 HSF: Human Splicing Finder. NNS: NNSplice. 
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Figure 7. Agarose gel electrophoresis (1%) of RT-PCR results of the wt MGBR2EX14-20  
minigene and its intermediate constructs, with the predicted fragment size. 
 
The Initial MGBR2 17-18 minigene showed an intron retention, but splicing reactions were 
stabilized by inserting the exon 16. Once the final minigene was obtained and it produced a 
correct splicing pattern, no additional material is needed (such as mRNA from patients), which 
avoids sample artifacts. Furthermore, the minigene usage leads to the analysis of an isolated 
allele (which easily allows the quantification of the different mRNA isoforms generated by a 
DNA variant). 
 
3.3 FUNCTIONAL ANALYSIS OF DNA SELECTED VARIANTS 
 
The selected variants were tested with a functional assay of mutant and wt minigenes. As a 
prior analysis, the Figure 8 contains the cDNA amplification results on an agarose gel, of each 
variant compared with a wild type sequence. This figure lets the identification of the main 
transcript produced by each variant, but its resolution is not enough to determine the details of 
every splicing pattern. In broad terms, the donor-associated variants had an altered splicing 
outcome, congruent with exon 17 skipping. 
 
  
Figure 8. Agarose gel electrophoresis (1%) of RT-PCR results of the wild type MGBR2EX14-20, and 
the selected DNA variants. Arrows indicate abnormal patterns/transcripts. 
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All transcripts were characterized by capillary electrophoresis of the FAM-labeled RT-PCR 
products and by DNA sequencing, results are summarized in Table 3. Besides the splicing 
outcome, the RNA and protein effect according to the HGVS nomenclature is also reported. 
Eight out of thirteen mutations (61.5%) had a consequence in the splicing process of exon 17 
of BRCA2. On next sections, each variant result is analyzed in detail. 
 
Table 3. Functional assay results of selected variants, with the RNA and protein effect.* 
* The variant c.7829dup could not be tested, since the site-directed mutagenesis was unsuccessful, despite the 
great effort on the standardization (annealing temperature, primer concentration and DMSO were tested, trying to 
obtain positive colonies). When we analyzed the mixed oligos duplexes formation, the variant c.7829dup had a very 
stable duplex at high temperature, which could lead to the experiment failure. 
 
 
CANONICAL-TRANSCRIPT ASSOCIATED VARIANTS 
 
Five variants showed no alteration of the canonical splicing pattern: c.7806-40A>G, 
c.7819A>C, c.7947A>G, c.7952G>T and c.7971A>G. Bioinformatic analysis indicated that 
c.7806-40A>G caused the disruption of a branch site; moreover, the other variants, which 
belong to a positive microdeletion region as is shown in Figure 9 (A), have been predicted to 
disrupt multiple enhancer sequences (such as SF2/ASF, SC35, SRp40 and SRp55) and to 
create silencer-binding sites. In addition, Figure 9 (B) shows the variant’s capillary 
electrophoresis, compared to a wild type transcript; and Figure 9 (C) shows the representation 
of the canonical transcript splicing pattern. Two variants induced predicted missense 
mutations: c.7819A>C (p. Thr2607Pro) and c.7952G>T (p. Arg2651Met).  
 
DNA variant Splicing outcome RNA effect Protein Effect 
c.7806-40A>G Canonical transcript - - 
c.7806-2A>G 
Alternative site usage 19 nt downstream 
(NNS: 0.17) (54.04%) Ex17 del20  
Alternative site usage 69 nt downstream 
(NNS: 0.54) (38.91%) Ex17 del69 
 Exon 17 skipping (7.05%)  
r.7806_7825del  
 
r.7806_7874del  
 
r.7806_7976del 
p. Ala2603Cysfs*8 
 
p.Ala2603_Arg2625del 
 
p.Ala2603_Arg2659del 
c.7806-1G>T 
Alternative site usage 19 nt downstream 
(NNS: 0.17) (96.85%) Ex17 del20  
Alternative site usage 69 nt downstream 
(NNS: 0.54) (3.15%) Ex17 del69 
r.7806_7825del  
 
r.7806_7874del 
p. Ala2603Cysfs*8 
 
p.Ala2603_Arg2625del 
 
c.7806insAG 
Alternative site usage 69 nt downstream 
(NNS: 0.54) (2.82%) Ex17 del69 
 Exon 17 skipping (1.42%)  
Exon17-insAG (95.76%) 
r.7806_7874del  
 
r.7806_7976del 
r.7805_7806insAG 
p.Ala2603_Arg2625del 
 
p.Ala2603_Arg2659del 
p. Ala2603Glyfs*46 
c.7819A>C Canonical transcript - p. Thr2607Pro 
c.7947A>G Canonical transcript - - 
c.7952G>T Canonical transcript - p. Arg2651Met 
c.7971A>G Canonical transcript - - 
c.7975A>G 
Exon 17 skipping (8.31%)  
Canonical transcript (91.69%) 
r.7806_7976del 
p.Ala2603_Arg2659del 
p. Arg2659Gly 
c.7976G>C 
Exon 17 skipping (96.47%)  
Alternative site usage 150 nt upstream 
(NNS: 0.94) (3.53%) Ex17 del150 
r.7806_7874del  
r.7826_7976del 
p.Ala2603_Arg2659del 
p.Val2610_Arg2659del 
 
c.7976G>A 
Exon 17 skipping (97.51%)  
Canonical transcript (2.49%) 
r.7806_7976del 
p.Ala2603_Arg2659del 
p. Arg2659Lys 
c.7976+1G>A Exon 17 skipping (100%)  r.7806_7976del 
p.Ala2603_Arg2659del 
 
c.7976+5G>T Exon 17 skipping (100%)  r.7806_7976del 
p.Ala2603_Arg2659del 
 
17 
 
 
Figure 9. (A) Agarose gel electrophoresis (1%) of functional assays of BRCA2 exon 17 microdeletions 
(adapted from Acedo, A. (2013) doctoral thesis). (B) Capillary electrophoresis of FAM-RT-PCR 
products (blue peaks) of the wild type MGBR2EX14-20, and the selected DNA variants. The Liz-1200 
DNA size standard is shown as orange peaks. (C) Representation of the canonical splicing pattern. 
 
 
ACCEPTOR SITE ASSOCIATED VARIANTS 
 
The variants c.7806-2A>G, c.7806-1G>T and c.7806insAG, which affect the consensus 3’ 
splice site sequence, induced aberrant splicing patterns. The bioinformatic analysis evidenced 
that the two first mutations caused the disruption of the natural acceptor site, but also the 
elimination of different enhancers and the silencer creation (c.7806-2A>G and c.7806-1G>T 
disrupt a 9G8 and a SC35 site, respectively). On the other hand, c.7806insAG was predicted 
to disrupt an acceptor site by the MaxEnt algorithm, and to create an hnRNPA1 binding site. 
The databases classification of this variant differs from our results, since c.7806insAG is 
classified only as a frame shift mutation, when it actually represents an intronic duplication of 
the AG acceptor site (c.7806-2_7806-1dup). 
 
Figure 10 (A and B) shows the functional results, and 10 (C) schematizes the aberrant splicing 
patterns produced by these variants. c.7806-2A>G and c.7806-1G>T variants induced usage 
of two cryptic alternative acceptor sites, localized 19 and 69 nt downstream (exon 17-del19 
and exon 17-del69),  the first one with a higher proportion in both cases (54.04% and 96.85%). 
Moreover, c.7806-2A>G also induced exon 17 skipping (7.05%). Finally, the c.7806insAG 
mutation generated an apparently canonical transcript with a frame shift mutation (AG 
insertion; 95.76% of isoforms), as well as exon 17-del69 (2.82%) and exon 17 skipping 
(1.42%). The protein prediction effects of these variants include frame shift changes with 
premature termination codons (PTC), p. Ala2603Glyfs*46 (exon 17-insAG) and 
p.Ala2603Cysfs*8 (exon 17-del19), and two in-frame deletions, p.Ala2603_Arg2625del (exon 
17-del69) and p.Ala2603_Arg2659del (exon 17 skipping). 
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Figure 10. (A) Sequence and (B) capillary electrophoresis of RT-PCR products of c.7806-2A>G, 
c.7806-1G>T and c.7806insAG variants, compared to a wild type splicing outcome. The Liz-1200 DNA 
size standard is shown as orange peaks. (C) Representation of the aberrant-associated splicing 
patterns. 
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DONOR SITE ASSOCIATED VARIANTS 
 
Variants c.7975A>G, c.7976G>C, c.7976G>A, c.7976+1G>A, and c.7976+5G>T, which can 
be classified as part of the consensus 5’ splice site sequence, induced aberrant splicing 
patterns. The functional results and splicing pattern schemas are shown in Figure 11. The 
variant bioinformatic analysis, made through the NNSplice database, did not show the site 
disruption, since the exon 17 has a non-canonical donor sequence. However, other algorithms 
as MaxEnt from Human Splicing Finder detected changes in the atypical GC exon 17-donor 
site. Those changes were estimated to vary the scores as follows: -220%, -223%, -242%,            
-36%, and -67% respectively; therefore, a mutation within these sites should prevent 
recognition by the spliceosome. 
 
According to databases, the c.7975A>G mutation eliminates a SRp40 binding site. The relative 
isoforms quantification detected by capillary electrophoresis revealed the existence of two 
transcripts, a canonical one (which induces a predicted missense p.Arg2659Gly) with a 
percentage of 91.69%, and exon 17 skipping with 8.31%. The BIC database had annotated 
this variant as missense, nonetheless, the functional assay results showed how the exon 
skipping causes a BRCA2 in-frame deletion of 57 amino acids (p.Ala2603_Arg2625del) that 
correspond to the DNA binding region of BRCA2 (helical domain: amino acids 2479-2667). 
 
The following variants, c.7976G>C and c.7976G>A (annotated at BIC as missense), are 
substitutions of the last nucleotide of exon 17, and cause exon skipping in a major proportion. 
c.7976G>C causes exon 17 skipping in 96.47% of detected isoforms, and an alternative donor 
site recognition localized 150 nt upstream of the natural site (with a percentage of 3.53%). 
Similarly, c.7976G>A variant generates exon 17 skipping in high percentage (97.51%), but 
differs of the last one since it produces a canonical transcript in 2.49% of isoforms. 
Furthermore, the protein effect of such changes are in-frame deletions of 57 amino acids 
(which corresponds to exon 17 skipping, see above), and p.Val2610_Arg2659del, a deletion 
of 50 amino acids caused when an alternative donor 150 nt upstream is recognized. 
 
The c.7976+1G>A mutation also induces exon 17 skipping, but it does it in 100% of transcripts. 
Bioinformatics also predicted a disruption of a SRp40 binding site. The BIC database classified 
it as an intervening sequence; however, it affects an essential nucleotide of the donor site 
causing a deletion of 57 amino acids as is shown in Table 3 (p.Ala2603_Arg2625del).  
 
Finally, the c.7976+5G>T variant, induces exon 17 skipping in all the detected isoforms of the 
splicing outcome. This variant is considered and Unclassified Variant by the UMD database 
but here we demonstrated that c.7976+5G>T triggers the RNA isoform r.7806_7976del, and 
therefore, the predicted p.Ala2603_Arg2625del protein deletion, which belongs to the 
conserved DNA-binding domain, which could be probably associated with the disease. 
Interestingly, the splicing effect of this variant was replicated in a patient by lymphocyte RT-
PCR  (Infante and Durán, 2015. Cancer Genetics Laboratory, IBGM). 
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Figure 11. (A) Sequence and (B) capillary electrophoresis of variants c.7975A>G, c.7976G>C, 
c.7976G>A, c.7976+1G>A, and c.7976+5G>T, compared to a wild type splicing outcome. The Liz-
1200 DNA size standard is shown as orange peaks. (C) Representation of the aberrant-associated 
splicing patterns. 
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4 DISCUSSION 
 
The splicing is an important eukaryote cellular process, which plays a crucial role in the 
generation of biological complexity and genetic diversity. Pre-mRNA processing is an essential 
step in gene expression, regulated by a complex network of interactions; therefore, a disruption 
of any regulatory factor can have a determinative role in genetic diseases, as a direct cause, 
a modifier of disease severity, or a determinant of disease susceptibility (Faustino et al., 2003; 
Kaida et al., 2012; Wang and Cooper, 2007). Splicing aberrant patterns have also been 
associated with cancer initiation and progression, and are acquiring a growing relevance, being 
important in genetic testing, especially in hereditary cancer. In this way, the clinical 
classification of DNA variants regarding its effect on disease predisposition (which leads 
clinical management of patients and asymptomatic carriers) represents a challenge for 
geneticists; nonetheless, the identification of genomic variants that trigger aberrant splicing is 
not as simple.  
 
4.1 HYBRID MINIGENE APPROACH VALIDATION 
 
Although the study of RNA samples from patients is the ideal way to assess the splicing effect 
of DNA variants, this method has limitations that restrict a broad implementation. First, it is 
frequently difficult to obtain, since the patient sample might not be available and, second, the 
source of RNA could mask the actual splicing alterations because of the differential tissue-
specific alternative splicing events (leukocytes are used rather than HBOC target tissue) 
(Baralle et al., 2009). As a reliable and straightforward substitute methodology, ex vivo assays 
of DNA variants have emerged. Splicing reporter minigenes are valuable tools to corroborate 
bioinformatic data, which had been reported successful for the identification of BRCA1/2 
splice-site variants with impact on splicing (Acedo et al., 2012; Acedo et al., 2015; Anczuków 
et al., 2012; Cooper, 2005; Gaildrat et al., 2010; Gaildrat et al., 2012; Sanz et al., 2010). We 
attempted to use a splicing reporter strategy by implementing a hybrid minigene to study the 
candidate DNA variants on exon 17 of BRCA2. Functional minigene analysis represents a 
powerful tool to determine the biological and the pathological significance of sequence variants 
detected in genetic screenings of disease-predisposing genes (Gaildrat et al., 2010). The 
designed vector, pSAD, allows the cloning of any exon of any human disease gene, so that 
any real or theoretical mutation can be generated by site-directed mutagenesis, and tested 
under the splicing perspective in eukaryotic cells (where unique vector exon primers 
specifically amplify the minigene-synthesized RNA). Moreover, the methodological strategy is 
straightforward, consisting of the following steps: Cloning into pSAD- Transfection- RNA 
isolation- RT-PCR – Sequencing and quantification of induced transcripts by fluorescent 
capillary electrophoresis. 
 
Likewise, the high resolution of the fluorescent RT-PCR technique in splicing reporter assays 
should be highlighted as it allowed accurate detection of isoforms that otherwise could be 
masked. Its high resolution is capable of detecting minor transcripts; even less than 2% of total 
mRNA isoforms, which could not be visualized in agarose gels (see Figures 8, 10 and 11). 
Furthermore, the minigene approach is a single-allele assay that leads to a specific 
quantification of the different RNA isoforms without the normal allele interference (as in 
lymphocyte RT-PCR). Nevertheless, the success of this approach depends on the 
consideration of its main disadvantage: it may differ from the patient RNA analysis, since the 
genomic context (it has fewer inserted exons than the actual gene), and the control of the 
expression varies (it uses a different promoter). This could lead to changes in the expression 
level and transcription rate, influencing splicing process). In order to overcome the lack of 
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genomic environment, it is important to assure the correct exon recognition, by adding enough 
natural flanking exons to the analyzed one. 
 
As an example, a previous study showed the effect of genomic context on the splicing outcome 
generated by two different NF1 minigenes (Neurofibromatosis type I). The first one contained 
only the exon 37 of the NF1 gene, and the pathogenic variant 6792C>G was analyzed, which 
was found to principally induce exon 37 skipping. Conversely, a minigene with exons 31 to 38, 
with the same variant introduction, replicated almost exactly the splicing pattern of a patient 
sample (canonical transcript, exon 37 skipping and exons 36+37 skipping) (Buratti et al., 
2006). Moreover, our laboratory has already tested the influence of the genomic context on 
the functional analysis of variants through hybrid minigenes: in (Acedo, 2013), the c.8488-
1G>A mutation (corresponding to exon 19 of BRCA2), was analyzed by a patient lymphocyte 
RT-PCR, and by functional splicing assays in MGBR2EX19-20 and MGBR2EX19-27 
minigenes. The minigene results showed the presence of the two aberrant isoforms detected 
in the RT-PCR of lymphocytes; however, MGBR2EX19-20 also revealed a third transcript in 
major proportion (deletion of exon 20), differing from the patient pattern. When MGBR2EX19-
27 was used, it practically restored the lymphocyte-splicing pattern supporting the hypothesis 
of the flanking exons requirement for proper recognition. 
 
Consequently, larger minigene constructions with more exons should be carried out in order 
to mimic the natural genomic background. In the case of the MGBR214-20, we compared the 
minigene and lymphocyte RT-PCR results (using the c.7976+5G>T variant, which was 
evaluated in the Cancer Genetics Laboratory, IBGM), and showed the reliability of the 
minigene, which offers the sufficient genomic context for exon 17 study. Furthermore, another 
BRCA2 exon 17 variant (c.7976G>A) was studied in patient samples (Hofmann et al., 2003), 
being completely congruent with our results. To these findings must be added the previous 
exposed evidence, and the fact that the minigene contains proper flanking exons to exon 17, 
giving rise to the assertion that the genomic context of the MGBR2EX14-20 to this exon 
provides the required architecture for its successful recognition.  
 
4.2 VARIANT ANALYSIS: BIOINFORMATIC PREDICTION AND FUNCTIONAL ASSAYS 
 
In order to test the splicing effect of significant variants and increase the probability of 
identifying BRCA2 variants associated with HBOC, there was made a bioinformatic analysis 
of the sixty-six database reported variants. Bioinformatic predictions of DNA variants are 
useful, but only complementary, tools to identify possible splicing mutations because they must 
necessarily be confirmed by a functional assay. The algorithms used in those computational 
platforms are not enough precise by their own, because they systematically recognize all the 
degenerate motifs that can act as putative regulators. Their sensitivity can be increased by 
filtering the output data with other parameters such the motif evolutionary conservation, its 
strength, and the proximity of the splice sites (Fairbrother et al., 2004; Pettigrew et al., 
2005).The bioinformatic analysis of exon 17 of BRCA2 showed several features about it and 
its associated variants that were contrasted with the functional assay.  
 
First, the NNSPLICE software did not recognize the donor site of exon 17, which is attributed 
to the non-canonical nature of the 3’ consensus sequence. Nevertheless, other algorithms as 
HFS and MaxEnt could recognize it, giving the criteria to select these variants. The weak donor 
site of exon 17 of BRCA2 does not appear to be an obstacle to function as such, because the 
exon recognition process is combinatorial, in which a series of factors (site robustness, 
presence of splicing enhancers or enhancers, genomic context, secondary structure, 
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transcription kinetics, etc.) would facilitate accurate detection of donor and acceptor sites. 
Nevertheless, the imprecision of the computational analysis could lead to mask the variant 
effect determination; then, it is important to take this into account at the time of the variant 
selection for functional analysis, having a special carefulness on the ones that are located 
within the consensus sequence. Indeed, when these variants were functionally tested, they 
caused aberrant splicing patterns. 
 
Second, the current database annotation of BRCA1/2 variants has a classification, which is 
mostly based on the predicted protein translation, with several categories as frame shift, 
nonsense, missense, intervening sequence and synonymous. However, the functional 
analysis showed that except for the variants classified as synonymous, at least one mutation 
of each type has been found to affect the splicing process and therefore, the protein translation, 
which lead us to recommend that these variants be reclassified as spliceogenic. 
Reclassification of VUSs as deleterious under the splicing perspective will increase the number 
of HBOC families who may benefit from tailored prevention protocols. Consequently, aberrant 
splicing should be considered as a primary mechanism of pathogenicity, important in the study 
of VUSs, and complementary to the prediction of the protein effects (Sanz et al., 2010). 
 
In addition to bioinformatic analysis, we used a special criterion to select DNA variants for 
functional assays: if they were located within a positive microdeletion region previously 
identified, they would be prioritized. None of the variants that belonged to this region affected 
splicing, generating canonical transcripts. One way to explain this is the fact that cis-acting 
factors work additively: probably at the time of testing the variants individually, there was not 
a sufficient lack of regulation binding sites to alter exon recognition (i.e. the enhancer disruption 
and silencer creation, as the bioinformatic analysis predicted), as is evidenced in the complete 
microdeletion functional analysis, or we can even consider that selected variants do not affect 
active regulatory elements. Though these variants did not affect splicing, two of them cause 
missense changes with unknown clinical significance on the BRCA2 protein sequence: 
c.7819A>C causes a Thr to Pro amino acid change on the protein position 2607, and 
c.7952G>T causes an Arg to Met change on the 2651 position (whose possible functional 
effects on BRCA2 are being discussed on next section).  
 
Another variant that did not generate changes in the splicing pattern was c.7806-40A>G. 
Despite bioinformatics predicted that c.7806-40A>G disrupted a putative branch point, the 
functional assay showed a canonical transcript. The human branch point sequence is 
degenerate and its localization is highly variable, so its identification can be confusing and 
inaccurate; certainly, the human consensus BP has never been extensively explored in vitro 
(Gao et al., 2008). Therefore, there are two main explanations to the functional analysis results: 
first, the bioinformatic prediction was wrong; and second, after the BP sequence disruption, 
another sequence was used to generate the lariat structure. 
 
On the other hand, the positive functional results were obtained with the variants c.7806-2A>G, 
c.7806-1G>T, c.7806insAG, c.7975A>G, c.7976G>C, c.7976G>A, c.7976+1G>A and 
c.7976+5G>T. They generated four aberrant isoforms (Figures 10 and 11) that were caused 
by different splicing events including exon 17 skipping and use of alternative cryptic acceptor 
or donor splice sites. Moreover, most variants (Table 2) produced two or more distinct RNA 
isoforms. Our results are consistent with the literature, which indicates that the most common 
events of alternative splicing are exon skipping and alternative splice site selection, whereas 
intron retention is the less frequent phenomenon in physiological alternative splicing since this 
event is usually associated with changes in the reading frame and the introduction of 
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premature stop codons (Ast, 2004; Kim et al., 2008). In addition, these variants were located 
within the acceptor and donor consensus sequences, a fact that must be contextualized on 
the evolutionary conservation of these sites. Actually, the first, last and penultimate nucleotides 
of exons as well as the intronic positions +1 to +5 and -3 to -1 are also highly conserved and 
should be considered as potential splicing-affecting targets (Whiley et al., 2011). Therefore, 
this evidence suggests that the disruption of the splice sites is the causative mechanism, 
although some of them were not predicted to affect them (as it was explained before, on the 
non-canonical donor site).  
 
4.3 PUTATIVE PATHOGENICITY AND BRCA2 PREDICTED EFFECTS 
 
Taking all the results together, 12.1% of all the variants (8/66) of BRCA2 exon 17 are 
associated with splicing defects, being the second most frequent deleterious mechanism, after 
the truncating mutations, which represent the 21.2% (14/66). The splicing mutations generate 
different types of protein isoforms: two nonsense, three missense, and three protein deletions, 
combined according to the protein effects of the splicing outcome of each DNA variant. 
Regarding to the putative pathogenicity of aberrant splicing-associated variants, there are two 
basic criteria (Brandão et al., 2011): first, total or almost complete absence of the canonical 
transcript in the splicing outcome; and second, the presence of predicted aberrant effects on 
protein translation, such as introduction of frame shifts and premature stop codons or loss of 
essential domains of BRCA2.  
 
Seven out of eight variants fulfil these criteria (c.7806-2A>G, c.7806-1G>T, c.7806insAG, 
c.7976G>C, c.7976G>A, c.7976+1G>A and c.7976+5G>T), causing both the lack of canonical 
transcripts and protein modifications. It is important to clarify that c.7806insAG induces a frame 
shift, leading to the introduction of a premature stop codon, thus supporting a double 
deleterious mechanism: splicing disruption and protein truncation. These variants cause 
changes circumscribed to a highly conserved amino acids region of BRCA2 protein (see Figure 
12), the helical domain that has been described to be responsible of the interaction between 
the BRCA2 protein with DSS1 (deleted in split hand/split foot), and the FANCD2 binding 
domain. It has been suggested that the DSS1 proteins are required for the stability of BRCA2 
in mammalian cells (Li et al., 2006) and also has been implicated with normal cell growth in 
eukaryotes (Hofmann et al., 2003; Shahid et al., 2014), indicating an important role of exon 17 
in encoding a relevant domain for maintaining the proper function of the BRCA2 protein. 
Furthermore, the FANCD2 binding domain protein has a role in DNA repair, which is important 
to guarantee the BRCA2 protein functionality and then, the integrity of the genome during cell 
replication (De Oca et al., 2005; Van Der Groep et al., 2008).  
 
 
Figure 12. IARC BRCA2 alignment of the exon 17-corresponding amino acids (p.2603-2659). It 
contains the BRCA2 sequences from the following organisms: Homo sapiens, Pan troglodytes, 
Macaca mulatta, Rattus norvegicus, Canis lupus familiaris, Bos taurus, Monodelphis domestica, 
Gallus gallus, Xenopus tropicalis, Tetraodon nigroviridis, Takifugu rubripes and Strongylocentrotus 
purpuratus. Adapted from http://agvgd.iarc.fr/references.php 
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Additionally, two variants that generated canonical splicing patterns (c.7819A>C and 
c.7952G>T) induce missense mutations on the BRCA2 protein. The changes, p. Thr2607Pro 
p. Arg2651Met respectively, were identified within the IARC alignment (Figure 12) and then, 
tested in the PolyPhen-2 server (Adzhubei et al., 2010), in order to measure their possible 
effect on the protein functionality. The results indicate that p.Thr2607 is completely conserved 
within the BRCA2 alignment, and it was predicted as probably damaging on PolyPhem-2, with 
the maximum score of 1.0. On the other hand, p. Arg2651, is one of the most variable amino 
acid sites in the region (it has four different residues), but it was also classified as probably 
damaging, with a score of 0.983. This analysis shows how conserved the protein region is, 
and supports the idea of the deleteriousness of mutations within this domain.  
 
Another variant altered splicing, and c.7975A>G, maintaining a major proportion of canonical 
transcripts. It had weak impact on splicing since aberrant pattern accounted for only 8.31% of 
total detected isoforms. Then, the remaining question is how to elucidate the implication in 
carcinogenesis of mutations with incomplete splicing effects? Variants with strong effects, as 
it was explained, are probably deleterious since they inactivate critical protein functions. 
Nevertheless, the variants whose splicing effect is partial, such as c.7975A>G, have unknown 
effects on protein function, and it pathological role is more uncertain so that they would remain 
as unclassified variants.  
 
This question should be addressed by implementing an holistic study, including functional 
assays and epidemiological and statistical analyses (Easton et al., 2007). There must be taken 
into account the contribution of partial splicing mutations to a synergistic model of low-
penetrance alleles in HBOC susceptibility. In fact, there has been estimated that more than 
1,000 loci are involved in breast cancer susceptibility (Michailidou et al., 2013). All these 
parameters should be integrated in the definition of this cancer risk, and must include 
susceptibility and protector alleles, as well as environmental and life-style factors (Sanz et al., 
2010). All this, in order to provide an assessment of the individual risk, which seems to be one 
of the most laborious undertakings.  
 
5 CONCLUSIONS 
 
 Functional analysis of BRCA2 DNA variants was made through a hybrid minigene. It 
was constructed in the pSAD vector with exons 14 to 20, which allows the maintenance 
of the genomic context to exon 17. Therefore, it faithfully reproduces the physiological 
splicing reactions, avoiding the difficulty of the patient samples acquisition. This simple 
and reproducible approach analyzes the splicing impact of DNA variants by the 
introduction of them by site-directed mutagenesis, and uses the quantification of all 
splicing isoforms by the use of high-resolution capillary electrophoresis. 
 
 Bioinformatic analysis of DNA variants comprises useful predicting tools that help to 
select candidates for functional analysis. This type of study increases the probability of 
finding relevant variants with an effect on the splicing process regulation. Nevertheless, 
the accuracy of these computational tools varies according to the type of the regulatory 
element disruption: the prediction of mutations associated with canonical splice sites 
and the creation of alternative ones are more reliable than the predictions of enhancers 
and silencers.  
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 Eight out of thirteen analyzed DNA mutations (61.5%) altered the pre-mRNA 
processing of the BRCA2 exon 17. Seven of them can be likely classified as HBOC 
pathogenic variants (c.7806-2A>G, c.7806-G>T, c.7806insAG, c.7976G>C, 
c.7976G>A, c.7976+1G>A and c.7976+5G>T); the remaining one (c.7975A>G) has an 
incomplete effect on deleterious splicing, and the actual determination of its 
carcinogenic power requires further studies.  
 
 The results indicate that an important fraction of DNA variants are associated with 
splicing aberrations, and should be reclassified on databases; therefore, splicing 
disruption must be considered as a primary cause of gene inactivation, important in the 
study of unclassified DNA variants, so that splicing functional assays provide an added 
value for the genetic counseling of hereditary diseases. Thus, the reclassification of 
BRCA2 VUSs variants that affect splicing will significantly improve the genetic 
counseling procedure, increasing the number of HBOC families that can benefit from 
prevention protocols.  
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